犬異位性皮膚炎治療藥物市場，依藥物類別、依給藥途徑、依劑型、依配銷通路、地理位置

預計2024年犬異位性皮膚炎治療藥物市場價值為14.944億美元，預計到2031年將達到29.366億美元，2024年至2031年的年複合成長率（CAGR）為10.1%。

圖 1. 佔有率 (%)，依地區分類，2024 年

犬異位性皮膚炎是在家犬中觀察到的慢性皮膚病。其特徵是皮膚發炎和感染。在過去的幾十年裡，寵物狗中異位性皮膚炎的盛行率一直在增加。確切原因尚不清楚，但據信涉及遺傳和環境因素，導致免疫系統對通常無害的物質反應過度。患有異位性皮膚炎的狗狗會經歷嚴重的搔癢、發炎和皮膚損傷，導致不適。傳統上使用抗組織胺和皮質類固醇來控制症狀。然而，它們不能治癒這種疾病，長期使用會引起副作用。因此，需要能夠緩解症狀和改變疾病的安全有效的治療藥物。多家製藥公司正在投資研究和開發標靶生物製劑、免疫調節劑和其他新型治療方法。

市場動態：

全球犬異位性皮膚炎治療藥物市場受到寵物擁有量增加、研發活動增加、犬異位性皮膚炎盛行率增加以及新產品推出等因素的推動。近年來，市場見證了多種新藥的批准和上市，擴大了可用的治療選擇。然而，與新藥相關的高治療成本是一個限制因素。市場參與者有機會在未開發的新興市場中實現成長，並進一步開發先進療法。

研究的主要特點：

• 該報告對全球犬異位性皮膚炎治療藥物市場進行了深入分析，並提供了預測期（2024-2031）的市場規模（百萬美元）和年複合成長率（CAGR%），以2023年為基礎年。
• 它闡明了不同區隔市場的潛在收入成長機會，並解釋了該市場有吸引力的投資主張矩陣。
• 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
• 它根據以下參數介紹了全球犬異位性皮膚炎治療藥物市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
• 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球犬異位性皮膚炎治療藥物市場迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
• 利害關係人可以透過用於分析全球犬異位性皮膚炎治療藥物市場的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與假設

• 研究目標
• 假設
• 縮寫

第 2 章：市場範圍

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map (COM)

第 3 章：市場動態、法規與趨勢分析

• 市場動態
  • 促進要素
  • 限制
  • 機會
• 影響分析
• 市場走向
• 最近的發展
• 品牌和定價分析
• 監管場景
• 收購和合作場景
• 產品發布/批准
• 資金和投資
• PEST分析
• 波特的分析

第 4 章：全球犬異位性皮膚炎治療藥物市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章：2019 - 2031 年全球犬異位性皮膚炎治療藥物市場（依藥物類別）（百萬美元）

• 概述
• Janus 激酶抑制劑
• 抗組織胺藥
• 單株抗體
• 抗生素
• 過敏免疫治療/脫敏治療
• 其他

第 6 章：全球犬異位性皮膚炎治療藥物市場，依給藥途徑，2019 - 2031 年（百萬美元）

• 概述
• 可注射
• 口服
• 專題

第 7 章：全球犬異位性皮膚炎治療藥物市場，依劑型，2019 - 2031 年（百萬美元）

• 概述
• 平板電腦
• 乳霜
• 噴
• 其他

第 8 章：全球犬異位性皮膚炎治療藥物市場，依配銷通路，2019 - 2031 年（百萬美元）

• 概述
• 線上
• 離線

第 9 章：2019 - 2031 年全球犬異位性皮膚炎治療藥物市場（依地區）（百萬美元）

• 介紹
• 北美洲
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地區
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 印度
• 日本
• 東協
• 澳洲
• 韓國
• 亞太地區其他地區
• 中東
• 海灣合作理事會
• 以色列
• 中東其他地區
• 非洲
• 北非
• 中非
• 南非

第 10 章：競爭格局

• 公司簡介
  • Bioiberica SAU
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

第 11 章：分析師觀點

• 命運之輪
• 分析師觀點
• 連貫的機會圖

第 12 章：參考文獻與研究方法

• 參考
• 研究方法論

The canine atopic dermatitis treatment drugs market is estimated to be valued at USD 1,494.4 Mn in 2024 and is expected to reach USD 2,936.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.

Figure 1. Share (%), By Region, 2024

Canine atopic dermatitis is a chronic skin condition observed in domestic dogs. It is characterized by inflammation and infections of the skin. The prevalence of atopic dermatitis has been increasing among pet dogs over the past few decades. The exact causes are unknown, but it is believed to involve genetic and environmental factors that cause the immune system to overreact to substances that are normally harmless. Dogs with atopic dermatitis experience severe itching, inflammation, and skin lesions that lead to discomfort. Antihistamines and corticosteroids have traditionally been used to manage the symptoms. However, they do not cure the condition and long-term use can cause side effects. Therefore, there is a need for safe and effective treatment drugs that can relieve symptoms and modify the disease. Several pharmaceutical companies are investing in research and developing targeted biologics, immunomodulators, and other novel treatment approaches.

Market Dynamics:

The global canine atopic dermatitis treatment drugs market is driven by factors such as rising pet ownership, rising research and development activities, and increasing prevalence of canine atopic dermatitis, and new product launches. The market has witnessed the approval and launch of several new drugs in recent years which has expanded the treatment options available. However, high treatment costs associated with novel drugs is a restraint. The market players have opportunities for growth in untapped emerging markets and further development of advanced therapeutics.

Key Features of the Study:

• This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Bioiberica S.A.U, Dechra Pharmaceuticals PLC, Elanco, NIPPON ZENYAKU KOGYO CO., LTD, Vimian, TORAY INDUSTRIES, INC., Zoetis, Virbac, Ceva, Bimeda, Inc., Vivaldis, VetriMax Veterinary Products, Vetoquinol, and Royal Canin North America.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global canine atopic dermatitis treatment drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global canine atopic dermatitis treatment drugs market.

Detailed Segmentation-

• Drug Class:
  • Janus Kinase Inhibitors
  • Antihistamines
  • Monoclonal Antibodies
  • Antibiotics
  • Allergic Immunotherapy/Desensitization Therapy
  • Others
• Route of Administration:
  • Injectable
  • Oral
  • Topical
• Dosage Form:
  • Tablets
  • Creams
  • Spray
  • Others
• Distribution Channel:
  • Online
  • Offline
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bioiberica S.A.U
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Brand and Pricing Analysis
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Canine Atopic Dermatitis Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 impact on the market

5. Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Janus Kinase Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Antihistamines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Monoclonal Antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Allergic Immunotherapy/Desensitization Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Canine Atopic Dermatitis Treatment Drugs Market, By Dosage Form, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Tablets
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Creams
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Spray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Online
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Offline
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

9. Global Canine Atopic Dermatitis Treatment Drugs Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Regions, 2019-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Bioiberica S.A.U
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • Dechra Pharmaceuticals PLC
  • Elanco
  • NIPPON ZENYAKU KOGYO CO., LTD
  • Vimian
  • TORAY INDUSTRIES, INC.
  • Zoetis
  • Virbac
  • Ceva
  • Bimeda, Inc.
  • Vivaldis
  • VetriMax Veterinary Products
  • Vetoquinol
  • Royal Canin North America

11. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact